Evelo Biosciences, Inc. (EVLO): BCG Matrix [Apr-2026 Updated]

You're looking at Evelo Biosciences, Inc. (EVLO) through the classic BCG lens, but honestly, this isn't a typical portfolio review; it's an autopsy, given the company's November 2023 decision to dissolve. Forget finding a Star or a Cash Cow-the reality is stark: with TTM revenue at $0.00 and key pipeline assets like EDP1815 and EDP2939 halted after trial misses, the entire operation is functionally a 'Dog' asset pool, leaving only residual IP and cash equivalents of about $17.3 million as 'Question Marks' waiting for creditor payments. Let's break down exactly where the pieces of Evelo Biosciences, Inc. land in this grim matrix, because understanding the final state of a biotech firm after clinical failure is a lesson in itself.

Background of Evelo Biosciences, Inc. (EVLO)

You're looking at Evelo Biosciences, Inc. (EVLO) as of late 2025, and honestly, the picture is one of a company that has faced significant headwinds in its clinical development programs. Evelo Biosciences, Inc. is a clinical-stage biotechnology firm, founded back in 2014, based in Cambridge, Massachusetts. Its core mission revolves around pioneering oral medicines designed to act on immune cells within the small intestine, aiming to create systemic effects throughout the body.

The scientific engine behind Evelo Biosciences, Inc.'s efforts is its SINTAX platform. This technology focuses on modulating the gut-immune axis, which the company believes plays a central role in governing the immune, metabolic, and neurological systems. Their therapeutic candidates are generally either whole-microbe products or their extracellular vesicles (EVs), which is a novel approach to developing inflammation-resolving medicines.

When we look at the pipeline as of this late 2025 snapshot, we see a portfolio heavily impacted by clinical outcomes. For instance, EDP1815, a whole-microbe candidate, had progressed through Phase 2 trials for psoriasis and atopic dermatitis, though one of those indications saw development cease after a primary endpoint was missed due to an unusually high placebo response rate. Another key asset, EDP2939, their first oral EV product candidate, was being tested in a Phase 2 psoriasis trial, with earlier data anticipated in 2023.

The company also has other candidates in earlier stages. You'll find EDP1867, a non-live pharmaceutical preparation, which was in a Phase 1b clinical trial, and EDP1908, a product candidate specifically for oncology. It's important to note that Evelo Biosciences, Inc. does not pay a dividend, which isn't surprising for a clinical-stage biotech. As of late 2025, the company has a lean team, reporting 66 employees.

The market's current view of Evelo Biosciences, Inc. is stark. As of November 20, 2025, the stock was trading at a price of just $0.0005 per share, reflecting an extremely low market capitalization, and it trades on the OTC Markets (OTCMKTS) under the ticker EVLO. The trailing twelve-month Earnings Per Share (EPS) sits at a negative -9.65, which underscores the heavy investment phase this company is navigating.

Evelo Biosciences, Inc. (EVLO) - BCG Matrix: Stars

You're looking at the Stars quadrant for Evelo Biosciences, Inc. as of 2025, but honestly, the data points to a situation where this quadrant is entirely vacant. The company determined in November 2023 that it had no viable alternative but to proceed with dissolution, following a series of clinical setbacks.

The core reason for this is the complete failure of the pipeline to produce a commercialized product with high market share in a growing market. The high-growth potential that defines a Star simply evaporated when the key development programs did not meet their primary endpoints.

• Company determined to pursue dissolution in November 2023.
• No product achieved commercial sales or significant revenue.
• Core microbiome platform market opportunity is effectively zero for Evelo Biosciences, Inc.

The clinical development programs, which represented the only potential future Stars, were halted. EDP1815 development ceased for atopic dermatitis after the Phase 2 trial's fourth cohort did not meet the primary endpoint, showing an EASI-50 response of 37.9% compared to 44.7% for placebo at week 16.

Similarly, EDP2939 development was stopped after a Phase 2 trial in psoriasis showed an inferior outcome on the primary endpoint; only 19.6% of patients on EDP2939 achieved the PASI 50 score at week 16, versus 25% on placebo. This failure eliminated the next potential candidate.

Here's a quick look at the financial reality underpinning the decision to dissolve, which confirms the lack of any product generating cash flow to support a Star designation. The company had approximately $17.3 million in cash and cash equivalents as of September 30, 2023, which was being marshaled for winding down operations rather than investment in a high-growth asset.

The strategy, as executed by the board, was to monetize assets through Rock Creek Advisors to maximize recovery for creditors, not to invest in growth, which is the mandate for a Star. Consequently, there are zero commercialized products generating significant revenue to qualify as a Star for Evelo Biosciences, Inc. in 2025.

Evelo Biosciences, Inc. (EVLO) - BCG Matrix: Cash Cows

You're analyzing the Cash Cow quadrant for Evelo Biosciences, Inc. (EVLO) as of late 2025. Honestly, when we map the company's current financial reality against the classic definition of a Cash Cow-a market leader in a mature, low-growth market generating surplus cash-the picture is quite the opposite.

Cash Cows are the bedrock of a stable enterprise; they are the established brands that require minimal investment to maintain market share but pump out reliable, high-margin cash flow. This cash then funds the riskier ventures, like Question Marks. For Evelo Biosciences, Inc., this category is definitively empty.

• None; the company has no approved products on the market to generate stable, high-margin cash flow.
• The business model is entirely dependent on R&D funding, not product sales, which is the opposite of a Cash Cow.
• The company remains in the clinical-stage development of its pipeline candidates, such as EDP1815 and EDP2939.

The hard numbers confirm this lack of a revenue-generating base. A Cash Cow needs sales; Evelo Biosciences, Inc. reports zero sales activity over the last year.

The TTM revenue is reported as $0.00 as of late 2025, confirming a complete lack of a revenue base from commercialized products. This is the clearest indicator that no product currently qualifies as a Cash Cow. Instead of milking gains, the company is consuming capital to advance its pipeline.

The financial position shows a TTM Net Income of -$82.34M, indicating a significant cash drain, not a surplus. Furthermore, the TTM Free Cash Flow stands at -$73.99M. This negative cash flow is typical for a clinical-stage firm heavily invested in research and development, which is the very definition of a Question Mark or a Dog, not a Cash Cow. You can't fund administrative costs or shareholder returns from this position; you need external financing, as evidenced by the total funding raised of $167M over 4 rounds. Finance: draft 13-week cash view by Friday.

Evelo Biosciences, Inc. (EVLO) - BCG Matrix: Dogs

Dogs are business units or products operating in low market growth areas with a low market share. For Evelo Biosciences, Inc., the entire clinical-stage pipeline, including the lead candidates, are now defunct assets, fitting the profile of Dogs that should be avoided and minimized.

The strategic outcome for Evelo Biosciences, Inc. was the company's decision to pursue dissolution in November 2023, which confirms the entire business, in its operational form, is categorized as a 'Dog.' This action followed the failure of its key development programs to demonstrate sufficient commercial viability or clinical success to secure further financing.

The pipeline failures directly led to this classification:

• EDP2939 missed its primary endpoint in a Phase 2 psoriasis trial, leading to the cessation of its development.
• EDP1815 development for atopic dermatitis was halted after failing to meet its primary endpoint in Phase 2.

The financial reality underpinning this strategic shift is stark. As of the latest reported quarter preceding the dissolution announcement, the balance sheet reflected a significant negative equity position, which is a classic indicator of a unit that consumes capital without generating sufficient return.

The situation is further illuminated by the trailing twelve months (TTM) figures reported as of November 2025, reflecting the post-operational status:

• Revenue TTM: $0.00
• Net Income TTM: -$82.34M
• Free Cash Flow TTM: -$73.99M

The failure of EDP2939 in psoriasis was particularly telling; at the 16-week mark, only 19.6% of patients on the drug achieved the primary endpoint of at least a 50% improvement in Psoriasis Area and Severity Index (PASI 50) score, compared to 25% on placebo. This outcome made expensive turn-around plans unfeasible. The company's cash position was estimated to last only into the third quarter of 2023, necessitating the search for strategic alternatives that ultimately failed. Total liabilities of approximately $39.76 million exceeded total assets of $20.63 million, highlighting a negative equity position that made continued operation untenable.

The cessation of development for both lead candidates, EDP1815 and EDP2939, meant that the company's entire portfolio was comprised of assets with low market share potential in their respective development stages, which are prime candidates for divestiture or, in this case, complete write-down via dissolution.

Evelo Biosciences, Inc. (EVLO) - BCG Matrix: Question Marks

The Question Marks quadrant for Evelo Biosciences, Inc. (EVLO) is defined by the remaining, yet-to-be-monetized assets following the cessation of its clinical development programs and the initiation of formal dissolution proceedings as of late 2023. These assets, primarily the intellectual property and platform technology, reside in a high-growth sector-microbiome therapeutics-but carry a low realized market share due to the clinical failures of candidates like EDP1815 and EDP2939.

The core of these Question Marks is the remaining Intellectual Property (IP) and the Small Intestinal Axis (SINTAX) platform technology. This platform, designed to discover orally delivered, inflammation-resolving medicines, represents the potential future value. As of the last reported data, the company held 216 total documents, including applications and grants, structured around 17 total patent families. These figures represent the technical foundation that needed to be sold or licensed to generate a return.

These assets are consuming cash through the wind-down process, which is overseen by insolvency expert Craig Jalbert. The strategy has shifted from heavy investment to rapid divestiture or licensing to prevent further cash burn. The goal of the formal dissolution process is to pay creditors and potentially return residual cash to shareholders. This is the critical juncture where these assets must quickly convert to cash or risk being absorbed entirely by administrative and creditor claims.

The financial reality entering the dissolution phase is anchored by the last reported balance sheet figures. The remaining cash and cash equivalents were approximately $17.3 million as of September 30, 2023. This cash pool was designated for creditor payments. To maximize this pool, Rock Creek Advisors was tasked with identifying strategic alternatives to monetize the assets.

The potential value from the sale or licensing of the proprietary microbiome drug discovery platform is a key unknown in the Question Marks assessment. This value is intrinsically linked to the monetization of any remaining collaborations. While specific 2025 valuation figures for these assets are not public, the former collaborations, such as those with Massachusetts General Hospital or Dana-Farber Cancer Institute, represent potential licensing streams or sale components that could be realized during the asset liquidation phase.

Here's a look at the key financial and asset markers relevant to the Question Marks quadrant as the dissolution proceeds:

The Question Marks require a clear decision: invest heavily to capture market share or sell. Given the company's status, the action is definitively toward divestiture. The following points summarize the immediate focus for these assets:

• Monetize the SINTAX platform technology quickly.
• Finalize creditor payments from the cash reserves.
• Seek buyers for remaining IP and collaboration rights.
• Determine residual value for shareholders post-claims.
• The strategy is liquidation, not growth investment.